Developments in prognostic factors of acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Are combination therapies more effective for the treatment of relapsed refractory CLL?
A novel WINDOW of opportunity for young mantle cell lymphoma patients
Which CLL patients would benefit from intensive therapy?
How to manage relapsed/refractory MCL - new agents and unmet needs